Hepatic steatosis is a multifactorial condition that is often observed in obese patients and is a prelude to non-alcoholic fatty liver disease. Here, we combine shotgun sequencing of fecal metagenomes with molecular phenomics (hepatic transcriptome and plasma and urine metabolomes) in two well-characterized cohorts of morbidly obese women recruited to the FLORINASH study. We reveal molecular networks linking the gut microbiome and the host phenome to hepatic steatosis. Patients with steatosis have low microbial gene richness and increased genetic potential for the processing of dietary lipids and endotoxin biosynthesis (notably from Proteobacteria), hepatic inflammation and dysregulation of aromatic and branched-chain amino acid metabolism. We demonstrated that fecal microbiota transplants and chronic treatment with phenylacetic acid, a microbial product of aromatic amino acid metabolism, successfully trigger steatosis and branched-chain amino acid metabolism. Molecular phenomic signatures were predictive (area under the curve = 87%) and consistent with the gut microbiome having an effect on the steatosis phenome (> 75% shared variation) and, therefore, actionable via microbiome-based therapies.
H epatic steatosis is a multifactorial phenotype common to several chronic conditions, such as insulin resistance, atherosclerosis and fatty liver disease, with an increasing worldwide prevalence related to the obesity epidemic [1] [2] [3] [4] [5] . The gut microbiota recently emerged as a pivotal transducer of environmental influences (that is, dietary components and drug treatments) to exert protective or detrimental effects on several host tissues and systems, including regulation of intermediary metabolism, liver function and cardiovascular disorders, either directly via translocation or indirectly through microbial metabolism or function in metabolic disorders [6] [7] [8] [9] [10] [11] . Rodent studies have demonstrated the role of the gut microbiome in liver disease and to the stratification of type 2 diabetes and cardiovascular disorders. Microbiome-associated factors involve, for instance, bacterial lipopolysaccharide (LPS) or methylamines, such as trimethylamine (TMA) and TMA N-oxide (TMAO) 12, 13 , playing a part in the development of insulin resistance and atherosclerosis 6, 14, 15 . Hepatic steatosis is a shared mechanism for the development of type 2 diabetes and cardiovascular disorders in humans in both virus-associated and non-alcoholic fatty liver disease (NAFLD) 16 , but the physiological mechanisms behind this interplay remain poorly understood 17, 18 .
Here, we take advantage of the advances in high-throughput sequencing and phenotyping technologies to characterize in humans the physiological mechanisms that are responsible for the integrated interactions between signals from the gut metagenome and the host molecular phenome (a comprehensive set of molecular phenotypes useful to identify subgroups of patients 17 ) of hepatic steatosis. We introduce a unique integrative multi-omics and precision medicine approach combining shotgun metagenomics, liver transcriptomics, metabolomics in plasma and urine and clinical phenotyping to reveal the molecular mechanisms and multiscalar interactions involved in the physiology of steatosis in a new cohort of non-diabetic obese women that we recruited as part of the FLORINASH consortium.
In-depth analyses of fecal metagenomics and phenomics reveal a robust signature, highlighting a tight crosstalk between the microbiome, host gene expression and metabolism in hepatic steatosis involving low microbial gene richness (MGR) 19 and
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Metagenomic signatures of hepatic steatosis. To obtain detailed taxonomic and functional information in hepatic steatosis for the fecal microbiome, we sequenced the patients' fecal metagenome and data were processed using our in-house pipeline, performing quality control checks, filtering and binning of reads into taxonomic kingdoms ( Supplementary Table 3 and Supplementary Fig. 2) ; metagenome assembly 31 , gene prediction and clustering 32, 33 , functional annotation of gene clusters and comparison with the Human Microbiome Project Integrated Gene Catalog 34 were performed. A total of 19,140,155 predicted genes were identified, which formed 3,902,787 gene clusters. Of these genes, 2,320,286 mapped to the Integrated Gene Catalog, whereas 1,582,501 were novel (90% query length and 95% identity; Supplementary Table 4 ). We derived gene counts, that is, a measure of MGR, based on the average values obtained from 30 samplings of 7 million randomly sampled reads that mapped to genes 8 , resulting in a mean of 558,246 ± 154,249 genes across the samples ( Supplementary Table 5 ), which is in the same order of magnitude as previous reports 19 . Remarkably, MGR was significantly anti-correlated with hepatic steatosis ( Fig. 2a ; liver steatosis grade 0: 665,063 ± 126,062 versus liver steatosis grade 3: 517,989 ± 126,062 genes, n = 10 patients for both groups, P = 0.03 Wilcoxon rank-sum test) and with several markers of liver function, including γ -glutamyltransferase, alanine aminotransferase and inflammation (C-reactive protein), as well as with echography-assessed liver steatosis (Fig. 2b) . Our data demonstrate the association of MGR with liver steatosis in a BMI-adjusted context, reinforcing previous observations for body weight and liver cirrhosis 19 .
To determine whether specific microorganisms were responsible for this correlation, we assessed the abundance of prokaryotes within the metagenomes. Several taxa were significantly associated with liver steatosis and other related clinical parameters ( Fig. 2c -e, Supplementary Figs. 3a and 4 and Supplementary Table 6 ): at the phylum level, Proteobacteria, Actinobacteria and Verrucomicrobia were significantly correlated with liver steatosis, whereas Firmicutes and Euryarchaeota were significantly anti-correlated, and species diversity (calculated using the Chao1 estimator) was not correlated with liver steatosis ( Supplementary Fig. 3b ).
We next investigated the associations between microbial function, by mapping our microbial gene catalog onto Kyoto Encyclopedia of Genes and Genomes (KEGG) modules, and clinical phenotypes, thus revealing positive associations of hepatic steatosis with microbial carbohydrate, lipid and amino acid metabolism ( Supplementary  Fig. 5 ). These data indicate that a change in microbial metabolism may contribute to liver health in morbidly obese women. Of particular relevance, LPS and peptidoglycan biosynthesis was significantly correlated with liver steatosis ( Supplementary Fig. 5 ), with this increase in LPS biosynthetic potential being consistent with an increased representation of Gram-negative Proteobacteria in steatosis, as observed in rodents 35 . These pathway-level analyses also highlight an increase in bacterial biosynthetic potential for fatty acids, sugars and various amino acids, including BCAAs (valine, leucine and isoleucine) and AAAs (tryptophan, tyrosine and phenylalanine), associated with steatosis and insulin resistance; this increase in the level of BCAA biosynthesis further confirmed previous reports in obesity and insulin resistance contexts 28, 36 .
The effect of the microbiome on the hepatic steatosis phenome.
To reveal metabolic phenotypes that are possibly involved in steatosis related to the gut microbiome and liver steatosis, we performed metabolic profiling of urine and plasma by 1 H-NMR spectroscopy. A metabolome-wide association study 30 resulted in 124 metabolite signals in the urine and 80 in the plasma that correlated with hepatic steatosis and associated clinical traits ( Supplementary Figs. 6 and 7) . Strikingly, the majority of liver steatosis-associated metabolites in the plasma and urine were also associated with low MGR (Fig. 3a,b , Supplementary Fig. 8 and Supplementary Table 7 ). Among the top liver steatosis metabolites (also associated with low MGR), we observed a significant correlation with BCAA levels in the plasma (leucine probability false discovery rate (p-FDR) = 4.69 × 10 −5 ; valine p-FDR = 1.72 × 10 −4 ; isoleucine p-FDR = 9.72 × 10 −5 ; Fig. 3a ) and a significant increase in levels in the urine (leucine p-FDR = 6.1 × 10 −4 ; valine p-FDR = 1.73 × 10 −3 ; isoleucine p-FDR = 0.024; Fig. 3b ), consistent with reports in obese patients 20, 28 . Plasma choline and phosphocholine were not anti-correlated with liver steatosis for the 56 patients (but were anti-correlated in the larger cohort, n = 102; Supplementary Fig. 9 ), whereas increased choline excretion was observed in liver steatosis (Fig. 3b ), which is consistent with previous reports regarding choline bioavailability 6, 37 . Remarkably, urinary hippurate was associated with MGR, echoing similar associations recently observed with the Shannon diversity index obtained from 16S ribosomal RNA gene sequence profiling 38 . Among the microbial-mammalian co-metabolites significantly associated with steatosis and low MGR, plasma PAA (p-FDR = 4.69 × 10 −5 ) showed the strongest positive association ( Fig. 3a ). High MGR observed in non-steatotic patients was significantly correlated with numerous gut-derived microbial metabolites, such as urinary phenylacetylglutamine (p-FDR = 3.10 × 10 −9 ), plasma acetate (p-FDR = 0.009) and TMAO (p-FDR = 0.006) ( Supplementary Table 7 ), which is a microbial-host co-metabolite that has a role in insulin resistance and atherosclerosis 6, 14, 15 . We further confirmed that TMAO, but not TMA, was marginally anti-correlated with steatosis by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/ MS) using isotopically labelled standards 39, 40 , which is consistent with recent reports on the role of TMAO in metabolic homeostasis 15, 41 (Supplementary Table 8 ). Taken together, these results suggest Articles Nature MediciNe the existence of a metabolic phenotype associated with hepatic steatosis and low MGR, pinpointing elevated BCAA, AAA and microbial metabolite levels coupled to a potential imbalance in hepatic oxidation and conjugation of those microbial substrates.
To identify the hepatic molecular mechanisms associated with the gut microbiome, we complemented our phenome coverage by profiling hepatic (liver biopsy) transcriptomes from the same set of patients. We identified 3,386 and 3,201 genes that were significantly positively and negatively correlated, respectively, with liver steatosis (pSRC p-FDR < 0.05) ( Supplementary Table 9 ). Furthermore, 3,581 human genes were significantly correlated (p-FDR < 0.05) with MGR: the pathways associated with the 1,776 genes that were significantly positively correlated with MGR largely matched those that were significantly anti-correlated with steatosis ( Supplementary Fig. 10 ). However, the 1,805 genes that were anticorrelated with MGR matched those that were positively associated with hepatic steatosis ( Supplementary Fig. 10 ), consistent with an anti-correlation between liver steatosis and MGR ( Supplementary  Tables 9 and 10) .
To generate molecular hypotheses that could be useful for microbiota-related next-generation therapeutic strategies, we performed a hepatic signaling pathway impact analysis (SPIA 42 , see Methods) including the 2,277 genes that intersected the liver steatosis and MGR-associated genes. In particular, hepatic genes Articles Nature MediciNe associate with non-specific pathways involved in the core immune response to clearance of viral and bacterial (Proteobacteria and Gram-negative) infections (that is, viral carcinogenesis; such as pathogenic Escherichia coli infection and shigellosis), alcoholism and insulin resistance ( Fig. 3c ). Enrichment analyses (see Methods) of the hepatic genes that were significantly associated with MGR further highlighted a significant (p-FDR < 0.2) over-representation of KEGG pathways associated with the proteasome, phagosome, insulin resistance, glucagon signaling and non-specific responses to microbial (Gram-negative and viral) infections ( Fig. 3d ). Among the overlapping genes co-associated with hepatic steatosis and low MGR, LPL (which encodes lipoprotein lipase) was among the most correlated with hepatic steatosis, whereas ACADSB (which encodes short/branched-chain acyl-CoA dehydrogenase) and INSR (which encodes the insulin receptor) were the most anti-correlated ( Fig. 3e ), suggesting a molecular basis for the observation that individuals with low MGR have a reduced capacity to respond to insulin, which is exemplified by the decreased glucose disposal rate (during the EHC) and increased homeostatic model assessment of insulin resistance (HOMA-IR, as shown in Fig. 2b and previously reported in ref. 28 ). We further complemented our analyses of the hepatic transcriptome by assessing the topology of a directional network made of 2,277 genes that were significantly associated with liver steatosis and low MGR mapped onto KEGG pathways involved in liver disease, by aggregating all the KEGG networks with at latest one gene in common with the genes included in the NAFLD pathway. To analyze the topology of this resulting network, we computed the shortest paths between the significant genes and derived the betweenness centrality metric 43, 44 , that is, the number of shortest paths passing through a particular gene product, to evaluate how central these genes are in the network. Ranking of betweenness centrality from highest to lowest showed CREB3L4, PRKACA, CRTC2, OGT, INSR, NFKB1, PPP1CA, IKBKG, MAP3K7, MAPK9, ITGAV, RRAS2, RPS6KA2, PHKA1, PHKB, BRAF, ALDOC, PFKL, EFNA1, FGF12, ANGPT4, PDGFB, VEGFB, FGFR4, MAP2K2, TAPBP, ALDH3A2, ALDH7A1, GPI and GNAI3 to be the 30 genes that have the most control over the network. In particular, betweenness centrality further highlights clusters of central genes channeling a high proportion of the shortest paths involving cAMP-related genes (CREB3L4, PRKACA and CRTC2), innate immunity (NFKB1) and INSR, among others ( Fig. 3f ). Overall, hepatic gene expression is concordant with the metabolic signature obtained in the plasma and urine, showing elevated BCAA levels concomitantly associated with low MGR, liver steatosis and insulin resistance, highlighting the interconnection among these three parameters. Genetic manipulation of INSR in the hepatocyte displayed a NAFLD phenotype 45, 46 , and the gut microbiome has recently been shown in rodents to interfere with INSR activation in the liver 47 . These results in humans support numerous rodent-based hypotheses.
Steatosis-associated microbiota and microbial metabolites modulate the steatosis phenome.
Our results document a strong contribution of the gut microbiome to the hepatic steatosis phenome. The increased microbial capacity for metabolism of BCAAs and of Ultrasensitive CRP (mg dl -1 )
Fat mass (absolute, densitometry)
Fat-free mass (densitometry) γ-Glutamyltransferase Glucose (mg dl Table 6 for the exact and the BH-adjusted P values) are shown (d). Prokaryotic taxa that are significantly correlated with liver steatosis at the phylum and genus levels (n = 56, pSRC, two-sided, p-FDR < 0.05; see Supplementary Table 6 for the exact and the Benjamini-Hochberg (BH)-adjusted P values) are shown (e). For all panels, n = 56, groups as no liver steatosis = 10; liver steatosis 1 = 22; liver steatosis 2 = 14; liver steatosis 3 = 10. All boxplots are the median with the interquartile range, and the error bars are the 1.5-times interquartile range.
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AAAs, such as phenylalanine, tyrosine and tryptophan in liver steatosis ( Supplementary Fig. 5 )-phenylalanine metabolism resulting in PAA production-is supported by circulating metabolic markers ( Fig. 3a,b ), suggesting potential causal mechanisms involving the microbiome in the steatosis phenome. In particular, our results strengthen the contribution of the gut microbiome to increased levels of circulating BCAAs in the host 28,36 -a metabolic phenotype that is gaining a central role in metabolic disorders 20 . This disruption of the gut-liver axis is further exemplified by the increase in inflammatory response, endoplasmic reticulum stress and phagosome pathways associated with a decrease in insulin signaling and small-molecule catabolic processes, conceivably altogether contributing to impaired BCAA and AAA metabolism as well as detoxification of liver steatosis-associated microbial compounds. We then tested whether fecal microbial communities from donors with hepatic steatosis (steatosis grade 3) could trigger steatosis molecular mechanisms to recipient mice when compared with samples from donors with no hepatic steatosis (grade 0) ( Fig. 4a ). Donors with hepatic steatosis (n = 3, grade 3) were randomly selected. Among subjects without hepatic steatosis (n = 3, grade 0), we chose those that were similar in age, BMI and fasting glucose levels to those with steatosis. For instance, the fasting Articles Nature MediciNe glucose level was 87.3 ± 16.7 mg dl -1 in subjects without steatosis and 97.3 ± 6.4 mg dl -1 in the steatosis group (P = 0.39). After a short antibiotic treatment and washout period and four consecutive daily FMTs (as in refs. 48, 49 ), the recipient mice were fed a chow diet for 2 weeks. In the former group, this procedure resulted in a moderate but rapid accumulation of hepatic triglycerides (Fig. 4b) . We also observed an increase in Fabp4 expression and plasma valine concentration compared with mice that received samples from patients without liver steatosis ( Supplementary Fig. 11a,b) , showing the general effect of the steatosis-associated microbiota from human donors on mouse liver lipid accumulation. By permutation testing sevenfold cross-validated orthogonal partial least squares (O-PLS) models using the donor human microbiome composition, we could successfully predict recipient mouse phenome responses, especially for steatosis, hepatic triglyceride content, Fabp4 and plasma valine levels ( Fig. 4c and Supplementary Fig. 11c -e, 1,000 random permutations; see Methods), highlighting the statistical robustness of the prediction between human donor microbiomes and recipient mouse phenome. We then derived significant associations between the donor microbiota composition and the mouse phenome, showing that the steatosis-associated microbiota influences multiple patterns of association with hepatic triglycerides, circulating BCAAs and TMAO (Fig. 4d) . Similar yet weaker associations were also observed between the mouse phenome and recipient mouse microbiota evaluated by fecal 16S rRNA gene amplicon analysis ( Supplementary Fig. 12 ). The rapid hepatic lipid accumulation suggested a causal role of the human fecal microbiota in the triggering of hepatic steatosis, which, over a long-term period, could lead to a highly significant liver lipid depot, further contributing to hepatic insulin resistance. b, Hepatic triglycerides in recipient mice (control microbiome: n = 21 and steatosis microbiome: n = 23, two-sided t-test). c, Permutation tests for the goodness-of-fit (R 2 ) and goodness-of-prediction (Q 2 ) parameters obtained from a sevenfold cross-validated O-PLS regression model quantitatively predicting recipient mouse hepatic lipid accumulation from human donor microbiome composition (n = 44). d, Heatmap showing the association between human donor microbiota and recipient mouse phenome (n = 44, + indicates stastistical significance p-FDR< 0.05). Predictivity of O-PLS models was validated through 10,000 random permutations of the class membership variable and assessing the significance of the goodness-of-fit (R 2 , explained variance) and goodness-of-prediction (Q 2 , predicted variance) parameters. The horizontal axis corresponds to the correlation between the original class membership (on the right) and the permuted class membership (10,000 permutations on the left of the plot). The vertical axis corresponds to the R 2 (green dots) and Q 2 (blue dots) coefficients. Data obtained from FMT protocols were performed independently with fecal material from three patients with liver steatosis (grade 3: > 66% steatosis) and three control patients (grade 0: < 5% steatosis). Data are the mean ± s.e.m., *P < 0.05.
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To highlight the potential of novel microbial compounds to directly affect the hepatic steatosis phenome, we selected PAA owing to the convergence of metagenomic and metabolomic observations: (1) there is an increased abundance of microbial gene pathways associated with its production in metagenomic sequences ( Supplementary Fig. 5 ), and (2) it is the strongest microbial metabolite associated with steatosis in our metabolome-wide association study models (Fig. 3a) . We compared its effects with the effects of PA, a free fatty acid known to trigger hepatic steatosis in human primary hepatocytes 50 , using a full factorial design. We assessed lipid accumulation, the expression of genes involved in steatosis as well as BCAA metabolism and consumption. PAA initiates molecular mechanisms that lead to triglyceride accumulation in human primary hepatocytes in synergy with PA ( Fig. 5a,b ) and induces the expression of lipid metabolism genes (LPL and FASN; Fig. 5c,d) . PAA induced INSR expression contrary to PA and participated in the reduction of GLUT2 expression ( Fig. 5e,f) . We next investigated AKT phosphorylation, which was significantly lowered by PAA, suggesting that PAA reduces the response to insulin (Fig. 5g ). PAA increased ACADSB expression ( Fig. 5h ) and resulted in an increased utilization of BCAA from the cell medium ( Fig. 5i-k) . We then treated mice with PAA for 2 weeks and confirmed the increase in hepatic triglyceride levels and the decrease in excreted isoleucine (Fig. 5l,m) . These results suggest that PAA, as one of our top hepatic steatosis-associated microbial metabolites, significantly increases hepatic BCAA utilization and hepatic lipid accumulation.
Integrative data crosstalk and steatosis signatures. We finally quantified the crosstalk among gut microbiome, clinical phenotypes, liver transcriptome and urine and plasma metabolomes by estimating the proportion of shared variation among the different tables through RV coefficients ( Fig. 6 ; see Methods). A high proportion of information (79-97%) was shared between matching data sets ( Fig. 6a and Supplementary Table 11 ), suggesting a strong similarity between metagenomic and phenomic data: the weakest (79.44%) being between urinary metabolome and clinical parameters. The metagenomic data shared 92-93% similarity with clinical parameters, liver transcriptome and plasma metabolome, whereas they only shared 74.68% with the urinary metabolome. This statistical crosstalk analysis suggests that, although metagenomic and Articles Nature MediciNe phenomic data have strong similarity, there is still information attached to each original data set, which, if pooled together, could result in a robust signature. We then built a multivariate model integrating metagenomic, transcriptomic and metabolomic information by fitting an O-PLS discriminant analysis (O-PLS-DA) and tested its ability to correctly classify new samples during a sevenfold cross-validation through random permutation testing (Fig. 6b, 10 ,000 random permutations, P = 0.0029). We derived a bootstrapped receiver operating characteristic (ROC) curve for the cross-validated models, illustrating the ability of the model to correctly predict new samples (area under the curve (AUC) = 87%; Fig. 6c and Supplementary Table 12 ) of the binary prediction of steatosis (that is, steatosis versus no steatosis) using cross-validated scores derived from sevenfold cross-validation of the O-PLS-DA model (see Methods), thereby confirming the joint predictive power of molecular phenomics and metagenomics. The predictive power of the phenome model is driven by the hepatic transcriptome (AUC = 85%) that directly relates to the affected organ, but the excreted phenome and plasma metabolome both reached 73% and 79%, respectively. This AUC is particularly relevant as the non-invasive basal clinical data yielded 58%, which only increases through the addition of more invasive metabolic challenges (oral glucose tolerance tests and EHCs: AUC = 69%). Taken together, these predictive models based on molecular phenomics and metagenomics further support the idea that these molecular signatures used to generate hypotheses are robust and ultimately suggest that the link tethering the microbiome to hepatic steatosis is also robust.
Discussion
In this study, we performed an in-depth clinical characterization of well-phenotyped non-diabetic obese women from Spain and Italy. We then revealed molecular networks between the gut microbiome and the hepatic steatosis phenome in this population of morbidly obese women, through computational integration of individual metagenomes, metabolomes and hepatic transcriptomes with histological steatosis scores. The robustness of our phenome signatures and the experimental follow-ups show that hepatic steatosis is negatively associated with MGR and that the microbiome contributes to the steatosis phenome. The striking association between low MGR and hepatic steatosis is consistent with clinical and preclinical results, confirming the role of the microbiome in rodent models 7 of NAFLD and the role of MGR in metabolic disease 19, 51 . We then functionally characterized an increased gut microbial amino acid metabolism in steatotic subjects that has a profound effect on their liver transcriptome, biofluid metabolomes and liver fat accumulation, eventually leading to fatty liver. We found that an anti-correlation pattern between steatosis and MGR was valid for the most significant steatosis-associated genes and metabolites, thereby suggesting that the reduction in MGR is a key factor that imbalances microbiome metabolic pathways leading to a steatosisassociated phenome, as observed for obesity 19, 51 . From this tight crosstalk, we further depicted a coordinated disruption of the gutliver axis in hepatic steatosis that manifests itself across the fecal metagenome, hepatic transcriptome and biofluid metabolome. For instance, the increased Proteobacteria frequency in hepatic steatosis is mirrored by an increase in microbial-associated functional pathways related to endotoxin production and immune response in patients with steatosis-both at the hepatic and circulating levels. Our study further confirms the effect of LPS and putatively other microbial products on liver lipid accumulation in humans 52 , as previously proposed in rodent models 35 .
By integrating numerous biological measurements, our data analysis strategy implemented a detailed functional analysis of the patient fecal metagenomes and molecular phenomes, offering novel insights for the integrative physiology of hepatic steatosis. For instance, the increased microbial potential for BCAA production, a phenomenon already reported for insulin resistance and obesity 28, 36 , is mirrored by an increase in the BCAA pool in biofluids. In addition, our bioinformatic analysis of metagenomic sequences combined with metabolomic data suggested a direct role for microbial degradation of AAAs into PAA in patients with steatosis. Our preclinical studies in rodents and primary culture of human hepatocytes corroborated the role of this metabolite, among others, as an example of a microbially related metabolite involved in hepatic steatosis. By subsequently focusing on a unique microbiome-associated feature, such as PAA, which was selected through converging patterns observed in microbial gene functions and biofluid metabolomes, we identified a novel mechanism by which the microbiome facilitates steatosis, via increased BCAA utilization and AAA metabolism. While acknowledging the complexity of the microbiome-host interplay, it should be noted that, although PAA is an exemplar metabolite highlighted in our human data set, its effects here are limited to triggering steatosis-associated molecular mechanisms and it is unlikely to be the sole player in steatosis. The PAA effects are most likely part of a much broader, multifactorial process orchestrated by the microbiome and involving many factors that warrant further studies.
The demonstration that the fecal microbiota obtained from patients with steatosis (grade 3, > 66%) initiated hepatic lipid accumulation and affected the phenome of recipient mice through FMTs reinforces the causal role of the microbiota in steatosis. Not only did the human donor microbiota from patients with steatosis trigger hepatic triglyceride accumulation in recipient mice but it also affected their circulating metabolome and hepatic transcriptome, through an increase in circulating valine levels and an increased expression of genes involved in lipid metabolism. Moreover, the characteristics of the donor microbiota predict the extent of the phenomic response in the donor mice, which echoes recent reports on the prodromal role of the microbiota for metabolic response to diet in animal models 15, 53 and humans 54 . The successful replication of the steatotic phenotype using human donor material for FMT in mice represents a key translational link between metagenomic studies in patients with NAFLD, hepatic fibrosis or cirrhosis 8, 55, 56 and previous FMT studies that had only been established for NAFLD with mouse donors 7 .
Taken together, we propose a model in which the microbiome orchestrates three possibly complementary contributions to hepatic steatosis in obesity: (1) reduced MGR-indicative of deleterious changes in microbiome functions-can trigger steatosis and increase the BCAA pool; (2) microbially produced PAA and possibly other related metabolites facilitate hepatic lipid accumulation via a synergetic increase in BCAA utilization in the TCA cycle; and (3) microbially associated factors, such as LPS, induce inflammation in hepatocytes.
Similar to a previous study that examined the fecal metagenome of patients with liver cirrhosis 8 , our data indicate a slight shift of the fecal microbiome in patients with steatosis to one that is more similar to that found in the human small intestine and oral cavity. For example, patients with steatosis had fewer Lachnospiraceae and Ruminococcaceae, which are responsible for butyrate production, and were enriched in Acidaminococcus and Escherichia spp. Bacteroides spp. which were associated with insulin resistance; this is concordant with observations from a previous study 28 showing that Bacteroides vulgatus was one of the main species contributing to insulin resistance, and circulating BCAA levels in humans 28 .
In conclusion, this work offers a unique clinical resource and integrated analysis of metagenomics with molecular phenomics of hepatic steatosis in non-diabetic obese women coupled with experimental validations in cellular and animal models. Not only does our work further validate previous studies in humans 55 but it also confirms hypotheses formulated in rodent models, such as the role of LPS, in which the gut microbiome was shown to influence gene pathways involved in the immune system and metabolic disorders (that is, inflammation affecting host metabolism 7, 35, 57 ). Ultimately, this integrated database and modeling approach also suggests new, potentially causal mechanisms in hepatic steatosis involving BCAAderived and AAA-derived metabolites. Our investigations further support the view that the molecular crosstalk between the microbiome and its human host is of utmost importance for patient health and highlights the need for integrative analyses of metagenomes and broad-sense phenomes 58, 59 . Our study establishes a comprehensive understanding of the microbial factors affecting human metabolic disease states for precision medicine, thereby laying the groundwork for targeted FMT therapies and pharmacotherapies to promote hepatic metabolic homeostasis.
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Methods Primary human hepatocyte culture and treatments. Cryopreserved primary human hepatocytes were obtained commercially (Innoprot) and cultured with hepatocytes medium (Innoprot) supplemented with 5% FBS, 1% hepatocytes growth supplement (a mixture of growth factors, hormones and proteins that are necessary for culture of primary hepatocytes) and 100 U ml -1 penicillin and streptomycin. Human hepatocytes were grown on poly-l-lysine pre-coated cell dishes at 37 °C and 5% CO 2 atmosphere following the manufacturer's recommendations. Cells were treated 24 h after seeding with PAA, PA or a combination of both. Compounds were prepared as follows: 136.16 mg PAA (P16621, Sigma) were dissolved in 10 ml PBS and 27.84 mg PA (Sigma) in 1 ml sterile water to obtain both components at 100 mM stock solutions. BSA (5%) was prepared in serum-free DMEM and then mixed with PA stock solution for at least 1 h at 40 ºC to obtain a 5 mM solution. Human hepatocytes were treated with PAA 10 mM, PA 200 µ M or a combination of both for 24 h. BSA and PBS were used as vehicles. All experimental conditions were performed in four biological replicates.
After treatment, cells were washed with PBS and collected with Qiazol for RNA purification. Total RNA was extracted and purified using RNeasy Mini Kit (Qiagen) following the manufacturer's protocol. Gene expression procedures were assessed using LightCycler 480 Real-Time PCR System (Roche Diagnostics), using TaqMan technology suitable for relative genetic expression quantification. Fatty acid accumulation was tested with Oil Red O staining. Briefly, after treatment, cells were washed twice with PBS, fixed with paraformaldehyde 7% for 1 h and dipped in isopropanol 60% before staining with Oil Red O (Sigma) for 10 min at room temperature. Pictures were taken with an inverted microscope. For quantification, 100% isopropanol was added to elute Oil Red O and the optical density was monitored spectrophotometrically at 500 nm (Cytation5, Biotek). Finally, insulin resistance analysis was performed as follows: human hepatocytes were maintained in starvation for 1 h after treatment. Insulin (100 nM in serum-free DMEM medium) was used for stimulation of the insulin pathway for 10 min. Then, cells were collected and homogenized in 50 µ l lysis buffer (Cell Signaling Technology) and cell debris was discarded by centrifugation (for 10 min at 15,000 r.p.m. at 4 ºC). The amount of protein was determined using the Lowry assay (Bio-Rad). Protein extracts were separated by SDS-PAGE and transferred to nitrocellulose membrane by conventional procedures. Membranes were immunoblotted with phosphorylated (Ser473) AKT serine/threonine kinase (pAKT) and total AKT (Cell Signaling Technology). Anti-rabbit IgG coupled to horseradish peroxidise was used as a secondary antibody. Horseradish peroxidase activity was detected by chemiluminescence, and quantification of protein expression was performed using Scion image software. Cell-based assays were not performed in a blind manner.
PAA treatment in mice. Procedures were carried out according to the French guidelines for the care and use of experimental animals (Animal authorization agreement no. CEEA34.AFB/CP.082.12, validated by the University Paris Descartes Ethical Committee). Ten-week-old C57BL/6J mice (Janvier labs) were used for in vivo PAA treatments. Mice were maintained in a 12-h light/dark cycle with water and standard diet (65% carbohydrate, 11% fat and 24% protein) supplemented with or without 0.8% PAA (Sigma) for 2 weeks. The mouse experiments were not performed in a blind manner. Experimental groups (n = 10 control group; n = 7 PAA-treated group) were randomly allocated.
FMT in mice. All animal experimental procedures were approved by the local ethical committee (approval number 31-278) of Rangueil University Hospital (Toulouse, France). Fecal microbiota and fecal water transplantation were performed as previously described 48, 49 , so that 20 mg per day per mouse (8-weekold C57BL6 male, Charles River) were administered for 4 consecutive days. Briefly, six fecal samples from subjects with (n = 3) and without (n = 3) hepatic steatosis matched for age and BMI (see Supplementary Table 1 ) were suspended separately in sterile reduced PBS (N 2 gas and thioglycolic acid; Sigma Aldrich). The fecal matter was used to treat 8-week-old mice. First, eight mice per patient were treated for 7 days with an antibiotic mixture (neomycin, ampicillin and metronidazole as previously described 48, 49 ). A 4-day washout period ensured elimination of the antibiotics. The mice were then gavaged once a day for four consecutive days with the fecal matter suspended in the buffer. Two weeks later, the mice were killed, and the livers and plasma were collected and frozen before assay. The mouse experiments were not performed in a blind manner. Experimental groups were randomly allocated.
Western blot analysis (mouse and primary hepatocytes).
Proteins from liver tissue were extracted from whole-cell lysates. Proteins were subjected to 10% SDS-PAGE gels and electroblotted to nitrocellulose membranes. Rabbit polyclonal antibodies of AKT (9272, Cell Signaling), pAKT (Ser473; 4060, Cell Signaling) and pAKT (Thr308; 3038, Cell Signaling) were used at 1:1,000.
Recruitment of patients and processing of samples. All subjects gave written informed consent, validated and approved by the ethical committee of the Hospital Universitari Dr Josep Trueta (Comitè d'Ètica d'Investigació Clínica, approval number 2009 046) and Policlinico Tor Vergata University of Rome (Comitato Etico Indipendente, approval number 28-05-2009). The human subject cohort comprised 105 morbidly obese women at the Endocrinology Service of the Hospital Universitari de Girona Dr Josep Trueta (Girona, Spain, n = 44) and at the Center for Atherosclerosis of Policlinico Tor Vergata University of Rome (Rome, Italy; n = 61). Sample size was not determined by statistical methods and is comparable to other studies in the field 51, 55, 56 .
Inclusion criteria. Pre-established inclusion criteria were: all subjects were of Caucasian origin; the subjects reported a stable body weight 3 months preceding the study and were not given a liquid diet before surgery, and were free of any infections, including the use of antibiotics, 1 month before surgery and had no systemic disease.
Exclusion criteria. Pre-established exclusion criteria were: subjects with a known medical history of diabetes or self-reported use of hypoglycemic agents, the presence of liver disease, specifically hepatitis C virus infection and tumor disease, and subjects with thyroid dysfunction were excluded by biochemical work-up. Alcohol consumption of > 20 g per day was an exclusion criterion. Hepatitis B was routinely excluded before the surgical procedure (anti-HB virus antibodies). To avoid iron overload, serum ferritin was below 200 ng ml -1 in all subjects. Autoimmune hepatitis was excluded by histology and the exclusion of viral hepatitis. Alpha-1 antitrypsin deficiency was excluded by anamnestic data and clinical evidence. Drug-induced liver injury was excluded using a drug questionnaire.
Stool and biofluid samples from all of the subjects were obtained during the week before elective gastric bypass surgery, during which the liver biopsy was sampled. Liver samples were collected in RNAlater, fragmented and immediately flash frozen in liquid nitrogen before storage at − 80 °C.
Histology on liver biopsies (human).
The investigators were blind to group allocations. A pathologist and a radiologist in each center assigned groups independently. Liver biopsies were analyzed by a single expert pathologist. The liver samples were stained with H&E, Masson's trichrome and reticulin. Excessive hepatic fat accumulation, associated with insulin resistance, is defined by the presence of liver steatosis in > 5% of hepatocytes according to histological analysis 21, 22 .
Clinical biochemistry (human). Plasma glucose concentrations were measured in duplicate by the glucose oxidase method using a Beckman glucose analyser II (Beckman Instruments). Duplicate samples were used for plasma insulin determination by the immunoradiometric assay (Medgenix Diagnostics). The coefficients of variation (intra-assay) were 5.2% at a concentration of 10 mU l -1 and 3.4% at 130 mU l -1 . The coefficients of variation (inter-assay) were 6.9% and 4.5% at 14 and 89 mU l -1 , respectively. Total plasma cholesterol was measured by an enzymatic, colorimetric method through the cholesterol esterase-cholesterol oxidase-peroxidase reaction (Cobas CHOL2). HDL (high-density lipoprotein) cholesterol was quantified by a homogeneous enzymatic colorimetric assay through the cholesterol esterase-cholesterol oxidase-peroxidase reaction (Cobas HDLC3). Total plasma triglycerides were measured by an enzymatic, colorimetric method with glycerol phosphate oxidase and peroxidase (Cobas TRIGL). LDL (low-density lipoprotein) cholesterol was calculated using the Friedewald formula. Cortisol was determined by routine laboratory test 60 . EHC (human). Insulin action was determined by the EHC. After an overnight fast, two catheters were inserted into an antecubital vein, one for each arm, used to administer constant infusions of glucose and insulin and to obtain arterialized venous blood samples. A 2-h EHC was initiated by a two-step primed infusion of insulin (80 mU m 2 min -1 for 5 min, 60 mU m 2 min -1 for 5 min) immediately followed by a continuous infusion of insulin at a rate of 40 mU m 2 min -1 (regular insulin; Actrapid, Novo Nordisk). Glucose infusion began at minute 4 at an initial perfusion rate of 2 mg per kg per min, then was adjusted to maintain the plasma glucose concentration at 4.9-5.5 mmol l -1 . Blood samples were collected every 5 min for determination of plasma glucose and insulin levels. Insulin sensitivity was assessed as the mean glucose infusion rate during the last 40 min. In the stationary equilibrium, the amount of glucose administered (M) equals the glucose taken by the body tissues and is a measure of overall insulin sensitivity. A 75-g oral glucose tolerance test in accordance with the American Diabetes Association criteria was also performed 61 .
Metabolic profiling and phenotyping by 1 H-NMR spectroscopy. All 1 H-NMR spectra were acquired using Bruker DRX600 spectrometers running under TopSpin, with either a 5-mm TXI probe operating at 600.13 MHz or a 5-mm BBI probe operating at 600.44 MHz. All runs were carried out using Bruker BACS60 sample handling automation; prior to each run, the 90° pulse length was determined and set for the run. The field frequency was locked on D 2 O as solvent.
In all experiments, water suppression was carried out by noise irradiation during the 2-s recycle delay. For all experiments, 128 scans were recorded into 32K data points with a spectral width of 20 ppm, and an exponential function was applied to the free induction decay prior to the Fourier transformation, which resulted in a line broadening of 0.3 Hz. All urine and plasma NMR spectra were automatically phased, baseline corrected and referenced either to trimethylsilylpropionate (δ 0.0) nature research | life sciences reporting summary June 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Scion, R, Matlab, GraphPad and in-house metagenomic processing pipeline. Pipeline scripts and instructions for obtaining the independently distributed programs and databases are available from http://www.imperial.ac.uk/ bioinformatics-data-science-group/resources/software. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
